Mar­ket­ingRx roundup: Pfiz­er talks about its ‘Char­lie’ AI mar­ket­ing bot; Gilead pledges $12M for HIV pre­ven­tion

Pfiz­er opens up about its gen­er­a­tive AI mar­ket­ing plat­form: The drug­mak­er is rolling out a new ar­ti­fi­cial in­tel­li­gence plat­form for mar­ket­ing — named “Char­lie” af­ter its founder Charles Pfiz­er — and is one of chief mar­ket­ing of­fi­cer Drew Panayiotou’s “big bets” for 2024. Panayiotou de­scribed Char­lie as Pfiz­er’s “AI-pow­ered mar­ket­ing work­bench” in a LinkedIn post last week, not­ing it’s “de­signed to ac­cel­er­ate col­lab­o­ra­tion, ideation and cam­paign de­vel­op­ment” be­tween the com­pa­ny and its agen­cies around the world. More de­tails about the plat­form and Pfiz­er’s plans for its fu­ture were re­port­ed by Digi­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.